Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 15/100

Failure Rate

4.8%

1 terminated/withdrawn out of 21 trials

Success Rate

95.2%

+8.7% vs industry average

Late-Stage Pipeline

29%

6 trials in Phase 3/4

Results Transparency

95%

19 of 20 completed trials have results

Key Signals

19 with results

Enrollment Performance

Analytics

Phase 1
10(47.6%)
Phase 3
6(28.6%)
Phase 2
5(23.8%)
21Total
Phase 1(10)
Phase 3(6)
Phase 2(5)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (21)

Showing 20 of 21 trials
NCT03514641Phase 2Completed

An Integrated Assessment of the Safety and Effectiveness of Bexagliflozin for the Management of Essential Hypertension

Role: lead

NCT03197324Phase 1Completed

Bexagliflozin Drug/Drug Interaction Study With Digoxin

Role: lead

NCT02956044Phase 1Completed

Interaction of Bexagliflozin With Metformin, Glimepiride and Sitagliptin

Role: lead

NCT02558296Phase 3Completed

Bexagliflozin Efficacy and Safety Trial

Role: lead

NCT03259789Phase 3Completed

Safety and Efficacy of Bexagliflozin Compared to Placebo as Add-on Therapy to Metformin in Type 2 Diabetes Subjects

Role: lead

NCT03296800Phase 1Completed

Study to Evaluate Effects of Probenecid, Rifampin and Verapamil on Bexagliflozin in Healthy Subjects

Role: lead

NCT01377844Phase 2Completed

Efficacy and Safety of EGT0001442 in Patients With Type 2 Diabetes Mellitus

Role: lead

NCT02836873Phase 3Completed

Safety and Efficacy of Bexagliflozin in Type 2 Diabetes Mellitus Patients With Moderate Renal Impairment

Role: lead

NCT02390050Phase 2Completed

A Dose Range Finding Study to Evaluate the Effect of Bexagliflozin Tablets in Subjects With Type 2 Diabetes Mellitus

Role: lead

NCT02715258Phase 3Completed

Safety and Efficacy of Bexagliflozin as Monotherapy in Patients With Type 2 Diabetes

Role: lead

NCT03115112Phase 3Completed

Safety and Efficacy of Bexagliflozin Compared to Sitagliptin as Add-on Therapy to Metformin in Type 2 Diabetes Subjects

Role: lead

NCT01029704Phase 2Completed

Safety and Efficacy Study of EGT0001442 in Subjects With Type 2 Diabetes Mellitus

Role: lead

NCT02820298Phase 1Completed

Study to Evaluate the Effects of a High-Fat Meal on Bexagliflozin in Healthy Subjects

Role: lead

NCT03557658Phase 1Completed

Safety and Efficacy of Bexagliflozin in Subjects With Moderate Hepatic Impairment

Role: lead

NCT03167411Phase 1Completed

Bexagliflozin Drug/Drug Interaction Study With Exenatide Injection

Role: lead

NCT02769481Phase 3Completed

Safety and Efficacy of Bexagliflozin Compared to Glimepiride as Add-on Therapy to Metformin in Type 2 Diabetes Subjects

Role: lead

NCT00485017Phase 2Completed

Efficacy and Safety of THR-4109 in Obese Subjects

Role: lead

NCT03417076Phase 1Withdrawn

Absolute Bioavailability Study With Bexagliflozin

Role: lead

NCT01155531Phase 1Completed

Safety & Tolerability of a Combination of Antidepressant and Peptic Ulcer Drug in Overweight Healthy Subjects

Role: lead

NCT00924053Phase 1Completed

Safety, Tolerability and Pharmacokinetics Study of EGT0001474 in Subjects With Type 2 Diabetes

Role: lead